GenMark Diagnostics plans to sell 10 million shares in public offering

Bookrunner J.P. Morgan assists; proceeds fund research and development

By Devika Patel

Knoxville, Tenn., June 19 - GenMark Diagnostics, Inc. plans to price a public sale of 10 million common shares, according to a preliminary prospectus supplement filed Tuesday with the Securities and Exchange Commission.

The deal has a greenshoe of 1.5 million additional shares.

J.P. Morgan is the sole bookrunning manager.

Proceeds will be used for research and development of the NexGen System, as well as expansion of the company's U.S. and global commercial organizations.

The molecular diagnostics company is based in Carlsbad, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.